Bristol-Myers Squibb reported positive results Monday in a crucial immunotherapy trial, using a combination of the two drugs Opdivo and Yervoy to treat patients with a specific type of non-small cell lung cancer patients.

But previously undisclosed changes made by Bristol to the study, known as Checkmate-227, are raising questions about the validity and strength of the results.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • This isn’t quite true. TMB was added as co-primary endpoint before the study enrollment stopped. PDL is still in trials which is continuing. TMB data on progression free survival showed enough impact it hit endpoint early so the data was released

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy